Daily Stock Analysis, INFI, Infinity Pharmaceuticals Inc, priceseries

Infinity Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.95
Close
0.99
High
1.01
Low
0.93
Previous Close
0.88
Daily Price Gain
0.11
YTD High
1.95
YTD High Date
Mar 14, 2019
YTD Low
0.82
YTD Low Date
Nov 7, 2019
YTD Price Change
-0.26
YTD Gain
-20.78%
52 Week High
2.40
52 Week High Date
Nov 9, 2018
52 Week Low
0.82
52 Week Low Date
Nov 7, 2019
52 Week Price Change
-1.41
52 Week Gain
-58.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
2.07
Feb 17. 2017
2.38
13 Trading Days
14.91%
Link
LONG
Feb 27. 2017
2.45
Mar 6. 2017
2.69
5 Trading Days
10.00%
Link
LONG
Sep 1. 2017
1.05
Sep 19. 2017
1.21
11 Trading Days
14.97%
Link
LONG
Oct 4. 2017
1.31
Oct 18. 2017
2.19
10 Trading Days
67.24%
Link
LONG
Nov 8. 2017
2.52
Nov 10. 2017
2.67
2 Trading Days
6.15%
Link
LONG
Mar 1. 2018
1.92
Mar 20. 2018
2.41
13 Trading Days
25.39%
Link
Company Information
Stock Symbol
INFI
Exchange
NasdaqGS
Company URL
http://www.infi.com
Company Phone
6174531000
CEO
Adelene Q. Perkins
Headquarters
Massachusetts
Business Address
784 MEMORIAL DRIVE, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001113148
About

Infinity Pharmaceuticals, Inc. is an innovative drug discovery and development company, which engages in discovering, developing and delivering medicines for difficult-to-treat diseases, developing novel small molecule drugs that target emerging disease pathways. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.